search

Active clinical trials for "Gram-Positive Bacterial Infections"

Results 21-30 of 42

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin...

InfectionsGram-positive Bacterial

Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.

Completed9 enrollment criteria

Telavancin Pediatric PK Study (Ages >3 Months to 17 Years)

Gram-Positive Bacterial Infections

This is a multicenter, open-label, single-dose pharmacokinetic (PK) study. Infants, children, and adolescents will receive a single 10 mg/kg dose of telavancin infused intravenously (IV) over 60 minutes

Terminated6 enrollment criteria

Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women...

Streptococcal InfectionGram-positive Bacterial Infection1 more

The study investigated the immune response induced by the Group B streptococcus vaccine in healthy pregnant women. In addition, the study investigated the amount of vaccine induced antibodies which were transferred to the newborn.

Completed27 enrollment criteria

Dalbavancin Outpatient Pilot

Gram-Positive Bacterial InfectionsSoft Tissue Infections

The purpose of this research is to determine if a new antibiotic called dalbavancin will work to treat and cure certain infections while reducing the need for daily antibiotics by vein.

Withdrawn30 enrollment criteria

Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and...

Streptococcal InfectionsGram-Positive Bacterial Infections1 more

The study compared the magnitude of the antibody response and safety of a GBS Trivalent Vaccine in HIV positive and HIV negative pregnant women and their offspring. In addition the study investigated the maternal to fetal transfer of antibodies induced by the investigational vaccine.

Completed4 enrollment criteria

Controlled Human Infection for Vaccination Against Streptococcus Pyogenes

Streptococcus Pyogenes PharyngitisStreptococcus Pharyngitis6 more

Group A Streptococcus (GAS) infection is a major cause of death and disability globally with a disproportionately high burden in settings of disadvantage worldwide. Acute infections due to GAS range from very common superficial skin infections (>150 million prevalent cases) and pharyngitis (over 600 million incident cases) to life-threatening invasive disease (>600,000 incident cases) such as necrotising fasciitis. Post-infectious GAS sequelae of GAS include acute rheumatic fever (ARF, ~500,000 incident cases) leading to rheumatic heart disease (RHD, ~34 million prevalent cases), and acute glomerulonephritis. The health services impact of GAS disease in all its forms is immense and strikes at every level from primary to intensive care. Controlled human infection models (CHIMs) have a long history of critical contributions to vaccine development. Data from CHIMs meeting modern scientific, regulatory, and ethical standards, are aiding efforts to control over 25 major human pathogens, including bacteria (e.g. pneumococcus, cholera), viruses (e.g. respiratory syncytial virus, influenza), and parasites (e.g. malaria, schistosomiasis). A reliable and safe controlled human infection model of GAS pharyngitis will be an important part of the global vaccine development effort. To build the model, the investigators are undertaking a dose-ranging study using an observational, dose-escalation, inpatient trial to determine the dose of GAS administered by direct oropharyngeal inoculation (bacteria 'painted' onto throat) required to reliably produce a pharyngitis attack rate of ≥ 60% in carefully screened healthy adult volunteers.

Completed45 enrollment criteria

Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven...

Gram Positive Bacterial Infection

This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 3 months to 24 months who have proven or suspected infections that are caused by a specific group of bacteria (called Gram-positive bacteria)or perioperative subjects that are receiving prophylactic antibiotics .

Completed4 enrollment criteria

Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe...

BacteremiaGram-Negative Bacterial Infections6 more

The impact of continuous veno-venous haemofiltration (CVVH) on sepsis-induced multiple organ failure severity is controversial. We thus sought to assess the effect of early application of haemofiltration on the degree of organ dysfunction and plasma cytokine levels in patients with severe sepsis or septic shock.

Completed2 enrollment criteria

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They...

Gram-positive Bacterial Infections

The purpose of this study is to evaluate the pharmacokinetics of a single dose of daptomycin in patients aged 2-17 years old who have a suspected or proven gram-positive infection for which they are receiving standard antibiotic therapy. The tolerability of a single dose of daptomycin in these patients will also be assessed.

Completed16 enrollment criteria

Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically...

Gram-Positive Bacterial InfectionsNephrotoxicity1 more

This is a randomized, controlled multicenter clinical trial. The purpose of this study is to compare the continuous infusion of vancomycin with intermittent infusion regarding the effectiveness to reach the target serum level and the relationship between infusion type and nephrotoxicity in critically ill patients.

Unknown status8 enrollment criteria

Need Help? Contact our team!


We'll reach out to this number within 24 hrs